https://www.selleckchem.com/products/Y-27632.html
Data of inflammation models showed significant (p 0.05) anti-inflammatory effects of RsSO in both acute and chronic models. 500 mg/kg RsSO halted inflammation development significantly better (p 0.05) as compared with lower doses. Histopathological evaluations of paws showed minimal infiltration of inflammatory cells in RsSO-treated animals. Findings of TNF-α ELSIA and docking studies showed that RsSO has the potential to downregulate the expression of TNF-α, iNOS, ROS, and NF-κB, respectively. Moreover, RsSO showed in vivo an